Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRG Bullfrog AI	$1.28 +0.8%	$1.54	$1.23 ▼ $4.84	$12.80M	0.47	173,122 shs	167,841 shs
CMND Clearmind Medicine	$1.02 +2.0%	$0.96	$0.80 ▼ $2.18	$4.27M	0.96	310,836 shs	69,401 shs
EDSA Edesa Biotech	$2.17 +2.8%	$2.12	$1.55 ▼ $5.00	$14.85M	0.27	28,694 shs	18,232 shs
TXMD TherapeuticsMD	$1.11 +2.3%	$1.15	$0.70 ▼ $2.44	$12.50M	0.42	22,750 shs	36,398 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRG Bullfrog AI	0.00%	-2.31%	-15.89%	-33.85%	-50.78%
CMND Clearmind Medicine	+1.32%	+2.04%	+5.20%	+2.04%	-15.25%
EDSA Edesa Biotech	+0.47%	-6.17%	+1.91%	+6.50%	-55.99%
TXMD TherapeuticsMD	+1.41%	-1.82%	-8.47%	-28.95%	-37.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRG Bullfrog AI	2.1074 of 5 stars	0.0	5.0	4.4	2.5	0.0
CMND Clearmind Medicine	0.4413 of 5 stars	0.0	2.0	2.8	1.7	0.0
EDSA Edesa Biotech	2.046 of 5 stars	2.0	5.0	2.6	1.7	0.6
TXMD TherapeuticsMD	1.2441 of 5 stars	0.0	5.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRG Bullfrog AI	0.00	N/A	N/A	N/A
CMND Clearmind Medicine	0.00	N/A	N/A	N/A
EDSA Edesa Biotech	4.00	Strong Buy	$5.00	130.41% Upside
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CMND, TXMD, EDSA, and BFRG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/27/2025	EDSA Edesa Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$5.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRG Bullfrog AI	$60K	215.04	N/A	N/A	$0.57 per share	2.25
CMND Clearmind Medicine	N/A	N/A	N/A	N/A	$0.73 per share	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.70 per share	N/A
TXMD TherapeuticsMD	$1.76M	7.26	N/A	N/A	$2.37 per share	0.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRG Bullfrog AI	-$6.99M	-$0.81	N/A	∞	N/A	N/A	-163.23%	-139.94%	8/13/2025 (Estimated)
CMND Clearmind Medicine	-$5.26M	-$1.10	N/A	∞	N/A	N/A	-164.79%	-71.12%	9/15/2025 (Estimated)
EDSA Edesa Biotech	-$6.17M	-$1.32	N/A	N/A	N/A	N/A	-162.95%	-60.33%	N/A
TXMD TherapeuticsMD	-$2.18M	N/A	0.00	∞	N/A	-114.07%	-7.86%	-5.46%	N/A

Latest CMND, TXMD, EDSA, and BFRG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	TXMD TherapeuticsMD	N/A	$0.05	N/A	$0.05	N/A	N/A
8/8/2025	Q3 2025	EDSA Edesa Biotech	-$0.26	-$0.25	+$0.01	-$0.25	N/A	N/A
6/12/2025	Q2 2025	CMND Clearmind Medicine	N/A	-$0.16	N/A	-$0.16	N/A	N/A
5/14/2025	Q2 2025	EDSA Edesa Biotech	-$0.30	-$0.30	N/A	-$0.30	N/A	N/A
5/13/2025	Q1 2025	BFRG Bullfrog AI	N/A	-$0.21	N/A	-$0.21	N/A	N/A
5/13/2025	Q1 2025	TXMD TherapeuticsMD	N/A	-$0.06	N/A	-$0.06	N/A	$0.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRG Bullfrog AI	N/A	N/A	N/A	N/A	N/A
CMND Clearmind Medicine	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRG Bullfrog AI	N/A	4.87	4.87
CMND Clearmind Medicine	N/A	1.74	1.74
EDSA Edesa Biotech	N/A	18.96	15.72
TXMD TherapeuticsMD	N/A	2.64	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRG Bullfrog AI	0.96%
CMND Clearmind Medicine	96.05%
EDSA Edesa Biotech	5.50%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
BFRG Bullfrog AI	33.90%
CMND Clearmind Medicine	N/A
EDSA Edesa Biotech	22.60%
TXMD TherapeuticsMD	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRG Bullfrog AI	4	10.08 million	6.22 million	Not Optionable
CMND Clearmind Medicine	N/A	4.27 million	N/A	Not Optionable
EDSA Edesa Biotech	20	7.04 million	5.44 million	Not Optionable
TXMD TherapeuticsMD	420	11.57 million	11.31 million	Optionable

CMND, TXMD, EDSA, and BFRG Headlines

Recent News About These Companies

TherapeuticsMD: Q2 Earnings Snapshot

4 hours ago | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12 at 4:05 PM | businesswire.com

TherapeuticsMD (NASDAQ:TXMD) Stock Price Up 0.5% - Should You Buy?

August 7, 2025 | americanbankingnews.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

TherapeuticsMD Inc. stock rises Monday, still underperforms market

May 12, 2025 | marketwatch.com

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day

April 8, 2025 | marketwatch.com

TherapeuticsMD Announces Full Year 2024 Financial Results

March 27, 2025 | businesswire.com

TherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo Finance

March 26, 2025 | finance.yahoo.com

TherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?

January 7, 2025 | bovnews.comB

TherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True Potential

January 3, 2025 | bovnews.comB

TherapeuticsMD Inc. stock remains steady Friday, still outperforms market

December 27, 2024 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains

November 23, 2024 | marketwatch.com

TherapeuticsMD Shifts Focus with Lower Q3 Losses

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Reports Reduced Losses Amid Strategic Shift

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Announces Third Quarter 2024 Financial Results

November 13, 2024 | finance.yahoo.com

TherapeuticsMD Inc. stock remains steady Monday, underperforms market

November 12, 2024 | marketwatch.com

TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

November 6, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMND, TXMD, EDSA, and BFRG Company Descriptions

Bullfrog AI NASDAQ:BFRG

$1.28 +0.01 (+0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$1.27 -0.01 (-0.78%)

As of 05:43 PM Eastern

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Clearmind Medicine NASDAQ:CMND

$1.02 +0.02 (+2.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.01 -0.01 (-0.69%)

As of 07:48 PM Eastern

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Edesa Biotech NASDAQ:EDSA

$2.17 +0.06 (+2.84%)

Closing price 03:54 PM Eastern

Extended Trading

$2.20 +0.03 (+1.38%)

As of 04:04 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

TherapeuticsMD NASDAQ:TXMD

$1.10 +0.03 (+2.31%)

Closing price 03:58 PM Eastern

Extended Trading

$1.11 +0.01 (+0.81%)

As of 07:56 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time